InMed Pharmaceuticals Inc (IN.TO)

Healthcare | Biotechnology
Income Statement (Quarterly) 2025-03-31 2024-12-31 2024-09-30 2024-06-30
Revenue 1,261,578,000 1,111,707,000 1,264,638 1,283,067
Cost of Revenue 1,085,953,000 650,813,000 771,225 6,990,016,107
Gross Profit 175,625,000 460,894,000 493,413 -6,988,733,040
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 1,328,996,000 1,553,583,000 1,421,926 1,213,931
Operating Expenses 2,238,649,000 2,613,950,000 493,413 466,071
Operating Income -2,063,024,000 -2,153,056,000 0 0
Interest Expense 0 0 0 0
Income Before Tax -2,120,930,000 -2,575,024,000 -1,677,868 -1,930,571
Income Tax Expense 0 0 0 7,100
Net Income -2,120,930,000 -2,575,024,000 -1,677,868,000 -1,937,671
Per Share
EPS -1.94 -3.64 -2.71 -0.22
EPS Diluted 0.00 0.00 0.00 0.00
Income Statement (Annual) 2025-06-30 2024-06-30 2023-06-30 2021-06-30 2020-06-30
Revenue 4,941,454 4,597,730 4,135,561 0 0
Cost of Revenue 3,235,274 3,496,817 2,732,525 0 0
Gross Profit 1,706,178 1,100,913 1,403,036 0 0
Operating Expenses
R&D Expenses 0 0 0 0 0
SG&A Expenses 6,556,257 5,250,715 5,847,518 4,479,333 3,978,829
Operating Expenses 9,409,496 9,015,743,000 9,781,823 9,938,283 8,867,885
Operating Income -7,703,317 0 -8,176,538,000 -9,938,283 -8,867,885
Interest Expense 373,105 0 0 360,350 18,616
Income Before Tax -8,160,186 -7,668,450 -7,934,522 -10,203,089 -8,681,266
Income Tax Expense 0 7,100 13,100 0 0
Net Income -8,160,186 -7,675,550 -7,947,622 -10,203,089 -8,681,266
Per Share
EPS -8.00 -1.01 -4.30 -1.95 -1.66
EPS Diluted 0.00 0.00 0.00 0.00 0.00
Balance Sheet (Quarterly) 2025-06-30 2024-06-30 2021-06-30 2020-06-30
Assets
Cash and Cash Equivalents 11,122,250 8,987,530 7,363,126 5,793,056
Short Term Investments 43,565 0 46,462 42,291
Net Receivables 467,051 482,551 11,919 45,244
Inventory 965,198 1,701,774 0 0
Total Current Assets 12,921,159 11,884,137 8,378,269 6,298,591
Property Plant Equipment 996,354 1,709,536 326,595 402,598
Goodwill and Intangibles 1,627,347 2,438,755 1,061,697 799,269
Total Assets 15,645,279 16,169,191 9,781,216 7,500,459
Liabilities
Account Payables 371,692 856,396 775,129 0
Short Term Debt 437,330 434,628 80,483 68,814
Total Current Liabilities 1,847,494 2,696,703 2,215,361 1,672,586
Long Term Debt 307,035 881,936 189,288 247,466
Total Liabilities 2,154,529 3,578,640 2,404,649 1,920,052
Shareholders Equity
Retained Earnings -117,728,813 -149,175,280 -74,852,470 -55,957,671
Total Shareholders Equity 13,490,750 12,590,550 7,376,567 5,580,407
Balance Sheet (Annual) 2025-06-30 2024-06-30 2021-06-30 2020-06-30 2019-06-30
Assets
Cash and Cash Equivalents 11,122,250 8,987,530 7,363,126 5,793,056 9,806,491
Short Term Investments 43,565 0 46,462 42,291 3,934,410
Net Receivables 467,051 482,551 11,919 45,244 64,737
Inventory 965,198 1,701,774 0 0 0
Total Current Assets 12,921,159 11,884,137 8,378,269 6,298,591 14,128,821
Property Plant Equipment 996,354 1,709,536 326,595 402,598 42,527
Goodwill and Intangibles 1,627,347 2,438,755 1,061,697 799,269 902,438
Total Assets 15,645,279 16,169,191 9,781,216 7,500,459 15,073,785
Liabilities
Account Payables 371,692 856,396 775,129 0 1,190,482
Short Term Debt 437,330 434,628 80,483 68,814 0
Total Current Liabilities 1,847,494 2,696,703 2,215,361 1,672,586 1,190,482
Long Term Debt 307,035 881,936 189,288 247,466 0
Total Liabilities 2,154,529 3,578,640 2,404,649 1,920,052 1,190,482
Shareholders Equity
Retained Earnings -117,728,813 -149,175,280 -74,852,470 -55,957,671 -49,185,035
Total Shareholders Equity 13,490,750 12,590,550 7,376,567 5,580,407 13,883,303
Cash Flow Statement (Quarterly) 2025-06-30 2024-06-30 2021-06-30 2020-06-30
Operating Activities
Net Income -5,990,842 -7,675,550 -10,203,089 -8,681,266
Depreciation & Amortization 392,477 604,518 120,866 221,218
Stock Based Compensation 87,569 137,714 610,193 1,252,593
Change in Working Capital -247,474 -369,338 -450,450 351,301
Operating Cash Flow -5,700,823 -6,985,832 -9,790,640 -9,767,400
Investing Activities
Capital Expenditure 0 -9,293 -1,725 -57,163
Investments 0 0 -1,725 -41,853
Investing Cash Flow 0 -9,293 -1,725 3,619,537
Financing Activities
Debt Repayment 0 0 0 -97,375
Common Stock Issued/Repurchased 5,318,655 4,654,043 12,472,500 0
Dividends Paid 0 0 0 0
Financing Cash Flow 9,006,824 4,654,218 10,854,722 -101,016
Summary
Free Cash Flow -5,700,823 -6,995,125 -9,792,365 -9,824,563
Net Change in Cash 3,305,846 -2,340,907 1,557,317 -4,961,805
Cash Flow Statement (Annual) 2025-06-30 2024-06-30 2021-06-30 2020-06-30 2019-06-30
Operating Activities
Net Income -5,990,842 -7,675,550 -10,203,089 -8,681,266 -10,096,772
Depreciation & Amortization 392,477 604,518 120,866 221,218 124,344
Stock Based Compensation 87,569 137,714 610,193 1,252,593 4,083,157
Change in Working Capital -247,474 -369,338 -450,450 351,301 283,892
Operating Cash Flow -5,700,823 -6,985,832 -9,790,640 -9,767,400 -8,768,573
Investing Activities
Capital Expenditure 0 -9,293 -1,725 -57,163 -35,491
Investments 0 0 -1,725 -41,853 -27,035
Investing Cash Flow 0 -9,293 -1,725 3,619,537 -2,105,609
Financing Activities
Debt Repayment 0 0 0 -97,375 0
Common Stock Issued/Repurchased 5,318,655 4,654,043 12,472,500 0 272,500
Dividends Paid 0 0 0 0 0
Financing Cash Flow 9,006,824 4,654,218 10,854,722 -101,016 207,572
Summary
Free Cash Flow -5,700,823 -6,995,125 -9,792,365 -9,824,563 -8,804,064
Net Change in Cash 3,305,846 -2,340,907 1,557,317 -4,961,805 -11,260,316